<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="http://localhost:8080/xmlui/handle/123456789/64">
    <title>DSpace Collection:</title>
    <link>http://localhost:8080/xmlui/handle/123456789/64</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="http://localhost:8080/xmlui/handle/123456789/2066" />
        <rdf:li rdf:resource="http://localhost:8080/xmlui/handle/123456789/2065" />
        <rdf:li rdf:resource="http://localhost:8080/xmlui/handle/123456789/2064" />
        <rdf:li rdf:resource="http://localhost:8080/xmlui/handle/123456789/2063" />
      </rdf:Seq>
    </items>
    <dc:date>2026-01-20T23:35:59Z</dc:date>
  </channel>
  <item rdf:about="http://localhost:8080/xmlui/handle/123456789/2066">
    <title>An open label, non-randomized, interventional study to evaluate the efficacy and safety of microneedling combined with 5-fluorouracil 5% cream versus microneedling combined with tacrolimus 0.1% ointment versus microneedling alone in clinically stable vitiligo patients</title>
    <link>http://localhost:8080/xmlui/handle/123456789/2066</link>
    <description>Title: An open label, non-randomized, interventional study to evaluate the efficacy and safety of microneedling combined with 5-fluorouracil 5% cream versus microneedling combined with tacrolimus 0.1% ointment versus microneedling alone in clinically stable vitiligo patients
Authors: REG NO: BT0122005
Abstract: Background: Vitiligo is a chronic, acquired depigmentation disorder characterized by the selective destruction of melanocytes, leading to the appearance of white macules on the skin. It affects approximately 0.5% to 2% of the global population and has a profound psychosocial impact despite its non-life-threatening nature. Various treatment modalities exist, including topical immunosuppressants, phototherapy, and surgical interventions, but none guarantee universal efficacy. Microneedling has emerged as a promising approach to enhance repigmentation, particularly when combined with pharmacological agents such as 5-Fluorouracil (5-FU) and Tacrolimus. However, limited comparative studies exist evaluating the efficacy and safety of these combinations in stable vitiligo.&#xD;
Aim and Objective: The primary objective of this study is to compare the efficacy of microneedling alone versus microneedling combined with 5-FU 5% cream and microneedling combined with Tacrolimus 0.1% ointment in patients with stable vitiligo. The secondary objective is to assess the safety profile and patient satisfaction associated with these treatment modalities.</description>
    <dc:date>2025-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://localhost:8080/xmlui/handle/123456789/2065">
    <title>Comparison of efficacy of topical janus kinase inhibitor tofacitinib used alone versus used in combination with targeted narrow-band ultraviolet b (excimer) therapy</title>
    <link>http://localhost:8080/xmlui/handle/123456789/2065</link>
    <description>Title: Comparison of efficacy of topical janus kinase inhibitor tofacitinib used alone versus used in combination with targeted narrow-band ultraviolet b (excimer) therapy
Authors: REG NO: BT0122004
Abstract: ABSTRACT&#xD;
BACKGROUND&#xD;
A chronic skin disorder which occurs due to loss of melanocytes and manifests with patches&#xD;
of depigmentation is categorized as vitiligo. Despite various treatment modalities, including&#xD;
corticosteroids and phototherapy, no definitive cure exists. Recent advances highlight that&#xD;
Janus Kinase inhibitors such as Tofacitinib play a role in regulating the immune mechanism&#xD;
associated with the pathogenesis of vitiligo. Hence, this study was undertaken. to compare&#xD;
the effectiveness of topical Tofacitinib alone versus its combination with narrowband&#xD;
ultraviolet B (NBUVB) therapy.&#xD;
AIMS AND OBJECTIVES&#xD;
To compare the effectiveness of topical JAK inhibitor (Tofacitinib) alone versus used along&#xD;
with concomitant phototherapy on de-pigmented lesions of vitiligo and to determine the effect&#xD;
of topical JAK inhibitor (Tofacitinib) on pigmentation in vitiligo lesions.</description>
    <dc:date>2025-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://localhost:8080/xmlui/handle/123456789/2064">
    <title>An interventional study comparing Intralesional verapamil and Intralesional triamcinolone acetonide In the treatment of keloids in a Tertiary care hospital</title>
    <link>http://localhost:8080/xmlui/handle/123456789/2064</link>
    <description>Title: An interventional study comparing Intralesional verapamil and Intralesional triamcinolone acetonide In the treatment of keloids in a Tertiary care hospital
Authors: REG NO: BT0122003
Abstract: ABSTRACT&#xD;
· Background: Keloids is caused by abnormal hyperproliferation of dermal&#xD;
fibroblast, causing expansion beyond boundaries of insult. Intralesional (IL)&#xD;
triamcinolone acetonide (TAC) causes inhibition of fibroblast. Intralesional&#xD;
verapamil, a calcium channel blocker activates procollagenase causing&#xD;
depolymerization of actin, inhibiting incorporation of proline and slowing action&#xD;
potential by which it reduces pain and pruritis associated with keloids. This study&#xD;
compares both the modalities for treatment of keloids.&#xD;
· Aims and Objectives: To assess and compare the efficacy, safety, reduction in&#xD;
pain and pruritis and side effects between intralesional verapamil hydrochloride&#xD;
and triamcinolone acetonide in treatment of keloid in patient aged 18 to 70 years.</description>
    <dc:date>2025-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://localhost:8080/xmlui/handle/123456789/2063">
    <title>An open label non-randomized split face interventional study to compare the efficacy and safety of microneedling with azelaic acid 10% gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma.</title>
    <link>http://localhost:8080/xmlui/handle/123456789/2063</link>
    <description>Title: An open label non-randomized split face interventional study to compare the efficacy and safety of microneedling with azelaic acid 10% gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma.
Authors: REG N0: BT0122002
Abstract: PRIMARY OBJECTIVE:&#xD;
To compare the efficacy of microneedling with azelaic acid 10 % gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma.&#xD;
SECONDARY OBJECTIVE:&#xD;
1. To compare the safety of microneedling with azelaic acid 10 % gel versus microneedling with tranexamic acid 5% gel in the treatment of melasma.&#xD;
2. To assess and compare Melasma Quality of Life (MelasQoL) score at the beginning and at end of the study.</description>
    <dc:date>2025-01-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

